U.S. launches tariff probe into Germany's pharmaceutical pricing policies

Summary

The U.S. has launched a tariff investigation into Germany's pharmaceutical pricing policies, accusing the country of "persistent underpayment" for medicines. U.S. Trade Representative Jamieson Greer expressed concern that American patients are bearing a disproportionate share of global pharmaceutical R&D costs, particularly as Germany fast-tracks legislation to further reduce its drug spending. The probe targets Germany's efforts to limit spiraling healthcare costs, which the U.S. argues unfairly shifts the financial burden of innovation onto American consumers.